Cel­lares rais­es $255M as it boosts its own man­u­fac­tur­ing ef­forts

Cel­lares, which is known for pro­duc­ing the tech­nol­o­gy used in cell ther­a­py man­u­fac­tur­ing, has raised $255 mil­lion in a Se­ries C as it aims to build out its own man­u­fac­tur­ing busi­ness.

The com­pa­ny’s think­ing is that con­tract man­u­fac­tur­ers are not cur­rent­ly able to meet glob­al de­mand, which has cre­at­ed a need for more CD­MOs with the tech­ni­cal know-how to man­u­fac­ture cell ther­a­pies, Cel­lares CEO Fabi­an Ger­ling­haus told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER